[1]
|
Carlsson, S.K., Brothers, S. and Wahlestedt, C. (2014) Emerging Treatment Strategies for Glioblastoma Multiforme. EMBO Molecular Medicine, 6, 1359-1370. https://doi.org/10.15252/emmm.201302627
|
[2]
|
Alifieris, C. and Tra-falis, D.T. (2015) Glioblastoma Multiforme: Pathogenesis and Treatment. Pharmacology and Therapeutics: The Journal of the International Encyclopedia of Pharmacology and Therapeutics, 152, 63-82.
https://doi.org/10.1016/j.pharmthera.2015.05.005
|
[3]
|
Harter, D.H., Wilson, T.A. and Karajannis, M.A. (2014) Glioblastoma Multiforme: State of the Art and Future Therapeutics. Surgical Neurology International, 5, 64. https://doi.org/10.4103/2152-7806.132138
|
[4]
|
国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022版) [J]. 中华神经外科杂志, 2022, 38(8): 757-777.
https://doi.org/10.3760/cma.j.cn112050-20220510-00239
|
[5]
|
Stupp, R., Hegi, M.E., Mason, W.P., et al. (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glio-blastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. The Lancet Oncology, 10, 459-466.
|
[6]
|
Johnson, D.R. and O’neill, B.P. (2012) Glioblastoma Survival in the United States before and during the Temozolomide Era. Journal of Neuro-Oncology, 107, 359-364. https://doi.org/10.1007/s11060-011-0749-4
|
[7]
|
Stupp, R., Mason, W.P., Van den Bent, M.J., et al. (2005) Radi-otherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996. https://doi.org/10.1056/NEJMoa043330
|
[8]
|
Bush, N.A.O., Chang, S.M. and Berger, M.S. (2017) Cur-rent and Future Strategies for Treatment of Glioma. Neurosurgical Review, 40, 1-14. https://doi.org/10.1007/s10143-016-0709-8
|
[9]
|
Lacroix, M., Abi-Said, D., Fourney, D.R., et al. (2001) A Multi-variate Analysis of 416 Patients with Glioblastoma Multiforme: Prognosis, Extent of Resection, and Survival. Journal of Neurosurgery, 95, 190-198.
https://doi.org/10.3171/jns.2001.95.2.0190
|
[10]
|
Orringer, D., Lau, D., Khatri, S., et al. (2012) Extent of Resection in Patients with Glioblastoma: Limiting Factors, Perception of Resectability, and Effect on Survival. Journal of Neuro-surgery, 117, 851-859.
https://doi.org/10.3171/2012.8.JNS12234
|
[11]
|
Oppenlander, M.E., Wolf, A.B., Snyder, L.A., et al. (2014) An Ex-tent of Resection Threshold for Recurrent Glioblastoma and Its Risk for Neurological Morbidity. Journal of Neurosur-gery, 120, 846-853.
https://doi.org/10.3171/2013.12.JNS13184
|
[12]
|
Sanai, N., Polley, M.Y., Mcdermott, M.W., et al. (2011) An Ex-tent of Resection Threshold for Newly Diagnosed Glioblastomas. Journal of Neurosurgery, 115, 3-8. https://doi.org/10.3171/2011.2.JNS10998
|
[13]
|
Kreth, F.W., Thon, N., Simon, M., Westphal, M., Schackert, G., Nikkhah, G., Hentschel, B., Reifenberger, G., Pietsch, T., Weller, M., et al. (2013) Gross Total but Not Incomplete Re-section of Glioblastoma Prolongs Survival in the Era of Radiochemotherapy. Annals of Oncology, 24, 3117-3123. https://doi.org/10.1093/annonc/mdt388
|
[14]
|
Bloch, O., Han, S.J., Cha, S., et al. (2012) Impact of Extent of Resec-tion for Recurrent Glioblastoma on Overall Survival: Clinical Article. Journal of Neurosurgery, 117, 1032-1038. https://doi.org/10.3171/2012.9.JNS12504
|
[15]
|
Lu, V.M., Goyal, A., Graffeo, C.S., Perry, A., Burns, T.C., Parney, I.F., Quinones-Hinojosa, A. and Chaichana, K.L. (2019) Survival Benefit of Maximal Resection for Glioblastoma Re-operation in the Temozolomide Era: A Meta-Analysis. World Neurosurgery, 127, 31-37. https://doi.org/10.1016/j.wneu.2019.03.250
|
[16]
|
Li, X.-Z., Li, Y.-B., Cao, Y., et al. (2017) Prognostic Implications of Resection Extent for Patients with Glioblastoma Multiforme: A Meta-Analysis. Journal of Neurosurgical Sciences, 61, 631-639.
https://doi.org/10.23736/S0390-5616.16.03619-5
|
[17]
|
Chaichana, K.L., Jusue-Torres, I., Navarro-Ramirez, R., Raza, S.M., Pascual-Gallego, M., Ibrahim, A., Hernandez-Hermann, M., Gomez, L., Ye, X., Weingart, J.D., et al. (2013) Establishing Percent Resection and Residual Volume Thresholds Affecting Survival and Recurrence for Patients with Newly Diagnosed Intracranial Glioblastoma. Neuro-Oncology, 16, 113-122. https://doi.org/10.1093/neuonc/not137
|
[18]
|
Chaichana, K.L., Cabrera-Aldana, E.E., Jusue-Torres, I., Wijesekera, O., Olivi, A., Rahman, M. and Quinones-Hinojosa, A. (2014) When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved? World Neurosurgery, 82, e257-e265. https://doi.org/10.1016/j.wneu.2014.01.019
|
[19]
|
Bette, S., Barz, M., Wiestler, B., Huber, T., Gerhardt, J., Buch-mann, N., Combs, S.E., Schmidt-Graf, F., Delbridge, C., Zimmer, C., et al. (2017) Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection. Annals of Surgical Oncology, 25, 558-564. https://doi.org/10.1245/s10434-017-6253-0
|
[20]
|
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O.D., Zanella, F., Reulen, H.-J. and ALA-Glioma Study Group (2006) Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial. The Lancet Oncology, 7, 392-401.
https://doi.org/10.1016/S1470-2045(06)70665-9
|
[21]
|
Coburger, J., Engelke, J., Scheuerle, A., Thal, D., Hlavac, M., Wirtz, C.R. and König, R. (2014) Tumor Detection with 5-Aminolevulinic Acid Fluorescence and Gd-DTPA-Enhanced Intraoperative MRI at the Border of Contrast-Enhancing Lesions: A Prospective Study Based on Histopathological As-sessment. Neurosurgical Focus, 36, E3.
https://doi.org/10.3171/2013.11.FOCUS13463
|
[22]
|
Coburger, J., Hagel, V., Wirtz, C.R. and König, R. (2015) Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival. PLOS ONE, 10, e0131872.
https://doi.org/10.1371/journal.pone.0131872
|
[23]
|
Schucht, P., Seidel, K., Beck, J., Murek, M., Jilch, A., Wiest, R., Fung, C. and Raabe, A. (2014) Intraoperative Monopolar Mapping during 5-ALA-Guided Resections of Glioblastomas Adjacent to Motor Eloquent Areas: Evaluation of Resection Rates and Neurological Outcome. Neurosurgical Focus, 37, E16.
https://doi.org/10.3171/2014.10.FOCUS14524
|
[24]
|
Acerbi, F., Broggi, M., Eoli, M., Anghileri, E., Cavallo, C., Boffano, C., Cordella, R., Cuppini, L., Pollo, B., Schiariti, M., et al. (2014) Is Fluorescein-Guided Technique Able to Help in Resection of High-Grade Gliomas? Neurosurgical Focus, 36, E5. https://doi.org/10.3171/2013.11.FOCUS13487
|
[25]
|
Neira, J.A., Ung, T.H., Sims, J.S., Malone, H.R., Chow, D.S., Samanamud, J.L., Zanazzi, G.J., Guo, X., Bowden, S.G., Zhao, B., et al. (2017) Aggressive Resection at the Infiltrative Margins of Glioblastoma Facilitated by Intraoperative Fluorescein Guidance. Journal of Neurosurgery, 127, 111-122. https://doi.org/10.3171/2016.7.JNS16232
|
[26]
|
Wu, J.-S., Gong, X., Song, Y.-Y., Zhuang, D.-X., Yao, C.-J., Qiu, T.-M., Lu, J.-F., Zhang, J., Zhu, W., Mao, Y., et al. (2014) 3.0-T Intraoperative Magnetic Resonance Imaging-Guided Resection in Cerebral Glioma Surgery. Neurosurgery, 61, 145-154. https://doi.org/10.1227/NEU.0000000000000372
|
[27]
|
Barone, D.G., Lawrie, T.A. and Hart, M.G. (2014) Image Guided Surgery for the Resection of Brain Tumours. Cochrane Database of Systematic Reviews, No. 1, CD009685. https://doi.org/10.1002/14651858.CD009685.pub2
|
[28]
|
Delgado-López, P.D. and Corrales-García, E.M. (2016) Survival in Glioblastoma: A Review on the Impact of Treatment Modalities. Clinical and Translational Oncology, 18, 1062-1071. https://doi.org/10.1007/s12094-016-1497-x
|
[29]
|
Garzon-Muvdi, T., Kut, C., Li, X. and Chaichana, K.L. (2017) Intraoperative Imaging Techniques for Glioma Surgery. Future Oncology, 13, 1731-1745. https://doi.org/10.2217/fon-2017-0092
|
[30]
|
Jakola, A.S., Unsgård, G. and Solheim, O. (2011) Quality of Life in Patients with Intracranial Gliomas: The Impact of Modern Image-Guided Surgery. Journal of Neurosurgery, 114, 1622-1630. https://doi.org/10.3171/2011.1.JNS101657
|
[31]
|
Moiyadi, A.V., Shetty, P.M., Mahajan, A., Udare, A. and Sridhar, E. (2013) Usefulness of Three-Dimensional Navigable Intraoperative Ultrasound in Resection of Brain Tu-mors with a Special Emphasis on Malignant Gliomas. Acta Neurochirurgica, 155, 2217-2225. https://doi.org/10.1007/s00701-013-1881-z
|
[32]
|
Hickmann, A.-K., Henkel, C., Nadji-Ohl, M., Hopf, N.J. and Renovanz, M. (2014) Navigated versus Non-Navigated Intraoperative Ultrasound: Is There Any Impact on the Extent of Resection of High-Grade Gliomas? A Retrospective Clinical Analysis. Journal of Neurological Surgery Part A: Central European Neurosurgery, 75, 224-230.
https://doi.org/10.1055/s-0033-1356486
|
[33]
|
Moiraghi, A., Prada, F., Delaidelli, A., Guatta, R., May, A., Bartoli, A., Saini, M., Perin, A., Wälchli, T., Momjian, S., et al. (2019) Navigated Intraoperative 2-Dimensional Ultrasound in High-Grade Glioma Surgery: Impact on Extent of Resection and Patient Outcome. Operative Neurosurgery, 18, 363-373. https://doi.org/10.1093/ons/opz203
|
[34]
|
Ganau, M., Ligarotti, G.K. and Apostolopoulos, V. (2019) Real-Time In-traoperative Ultrasound in Brain Surgery: Neuronavigation and Use of Contrast-Enhanced Image Fusion. Quantitative Imaging in Medicine and Surgery, 9, 350-358.
https://doi.org/10.21037/qims.2019.03.06
|